2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 958

Prevelance of Spondyloarthropathy in Fibromyalgia Patients
Abstract Number: 1325

Prevention of Joint Destruction in Patients with High Disease Activity or High C-Reactive Protein
Abstract Number: 153

Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
Abstract Number: 1551

Primary Angiitis of the Central Nervous System: Description of the First 52 Adult Patients Enrolled in the French COVAC’ Cohort
Abstract Number: 935

Primary Care Preventive Services in Patients with Systemic Lupus Erythematosus Compared to Others in Their Community
Abstract Number: 1654

Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Abstract Number: 1506

Primary Human Scleroderma Dermal Endothelial Cells Exhibit Defective Angiogenesis
Abstract Number: 2016

Primary Raynaud’s Phenomenon in a Multicenter Cohort of Italian Children and Adolescents: Which Prognostic Relevance for Serological Tests?
Abstract Number: 2456

Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus
Abstract Number: 4

Pro-Inflammatory Effect of Extracellular RNA On Synovial Fibroblasts From Patients with Rheumatoid Arthritis
Abstract Number: 2576

Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells
Abstract Number: 575

Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients
Abstract Number: 914

Prognosis for the Year 2030: The Consultation Prevalence of Osteoarthritis in Sweden May Increase by 50%
Abstract Number: 2385

Prognostic Impact of HLA-B^*51 and HLA–A^*26:01 On Ocular Behcet’s Disease
Abstract Number: 1930

Progranulin Plays a Protective Role in the Pathogenesis of Inflammatory Bowel Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].